My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1313
    CAS #: 1194044-20-6Purity ≥98%

    Description: LY2811376 (LY-2811376; LY 2811376) is a novel, potent, selective and the first orally bioavailable non-peptidic β-secretase (BACE1) inhibitor with the potential for the treatment of Alzheimer's Disease (AD). It inhibits BACE1 with an IC50 of 239 nM, and is able to decrease Aβ secretion with EC50 of 300 nM. LY2811376 was identified by fragment-based screening, and was able to lower Aβ levels in a mouse model of Alzheimer's disease as well as in normal dogs. 

    References: J Neurosci. 2011 Nov 16;31(46):16507-16; J Neurochem. 2004 Dec;91(6):1249-59.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)320.36
    CAS No.1194044-20-6
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 16 mg/mL (49.9 mM) 
    Water: <1 mg/mL
    Ethanol: 64 mg/mL (199.8 mM)
    Solubility (In vivo)30% PEG400+0.5% Tween80+5% propylene glycol: 30 mg/mL 
    SynonymsLY2811376; LY-2811376; LY 2811376.

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: LY2811376 demonstrates concentration-dependent inhibition of hBACE1 with an IC50 of 239 and 249 nM against a small synthetic peptide or a larger chimeric protein substrate, respectively. LY2811376 treatment yields a concentration-dependent decrease in Aβ secretion in APP-overexpressing HEK293 cells. LY2811376 inhibits Aβ secretion with EC50 of ~100 nM in primary neuronal cultures of PDAPP transgenic mouse.

    Kinase Assay: The stock solution for each FRET peptide substrate is prepared at 30 mM in dimethylsulfoxide (DMSO). The huBACE1:Fc muBACE1:Fc preparation is concentrated through YM10 Centricon. to a final concentration of at least 7 mg/mL. The optimal enzyme concentration for each FRET peptide substrate is determined individually at 30μM FRET peptide substrate in 50 mM ammonium acetate, pH 4.6, 1 mg/mL BSA and 1 mM Triton X-100. The enzymatic efficiency (kcat /Km) of either of the BACE1 orthologs toward individual FRET peptide substrates at 15, 30 and 100μM is determined under the optimal conditions for each substrate. The progress of the reaction is monitored by measuring an increase of the emission signal at 420 nm with excitation wavelength set at 320 nm, using a GEMINI fluorescence plate reader. Amino acid conjugated aminobenzoate is used to convert the emission signal in the relative fluorescence units into the molar concentration of product generated in the reaction mixture. The initial phase of the timedependence curve is fitted with a linear function whose slope is used to calculate the initial rate for huBACE1:Fc toward each peptide substrate. The kcat /Km values are calculated from the linear dependence of the initial rate on the concentration of each peptide.  

    Cell Assay: The cytotoxicity in the HEK293Swe cell model is assessed using a CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay.

    In VivoAdministration of LY2811376 (10, 30, and 100 mg/kg doses) results in dose-dependent, significant reductions in Aβ, as well as sAPPβ and C99, the proximal cleavage products of APP proteolysis by BACE1 in APPV717F mouse model of Aβ pathology. After treatment with LY2811376 (5 mg/kg), reductions in Aβ1-x are observed in plasma, with a maximal 85% reduction observed from 4 to 12 h after dosing in beagle dogs.
    Animal modelPDAPP transgenic mice.
    Formulation & DosageDissolved in 7% Pharmasolve; 10, 30, and 100 mg/kg; p.o. administration

    J Neurosci. 2011 Nov 16;31(46):16507-16; J Neurochem. 2004 Dec;91(6):1249-59.

    These protocols are for reference only. InvivoChem does not independently validate these methods.


    Co-crystal structure of LY2811376 in BACE1 active site (flap not shown for clarity). J Neurosci. 2011 Nov 16;31(46):16507-16. 


    Pharmacologic effects in vivo of oral administration of LY2811376. J Neurosci. 2011 Nov 16;31(46):16507-16. 


    LY2811376-related changes in the retinal epithelium of Sprague Dawley [Crl:CD(SD)] rats (top) and BACE1−/− knock-out (BACE1tm1Pcw) mice (bottom). J Neurosci. 2011 Nov 16;31(46):16507-16. 


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?